ALK and non-small cell lung carcinoma: However, recent pooled analysis found that EGFR mutations and ALK rearrangements were associated with low response rates to PD-1 pathway blockade in NSCLC (mainly in lung adenocarcinoma).[54] This retrospective analysis suggests that the immune therapy of PD-1 pathway blockade may not work so well in EGFR mutated NSCLC patients and EGFR mutation targeted therapy by EGFR TKI in EGFR mutated patients might be a very important selection.